Big Pharma Companies Deepen AI Connections: What It Means for Novo and Novartis

The deepening of AI connections by major pharmaceutical companies could be seen as a positive development for Novartis. Technical indicators, with the MACD above its signal line and the RSI around 50, support short‑term upside potential. The price is above the 20‑day moving average but slightly below the 50‑day average, signaling a mild recovery. Within 1–3 days, the news could drive a modest upward move toward the 152–155 range. However, market volatility and other news flows may constrain this movement.

News about AI integration by large pharmaceutical companies could generate a positive sentiment for NVO. A 24‑hour rise of 3.49% and trading above the 20‑day SMA may provide short‑term support. However, the MACD remains below the signal line and the RSI is around 60, indicating a risk of overbought conditions. A modest price rebound may be expected within 1‑3 days, but a gradual increase rather than a sharp spike is forecasted. Investors are advised to continue monitoring technical indicators and the long‑term impact of the news.